By concurrently targeting distinct molecular pathways or cellular processes, such as FAS inhibition and Her-2 blockade, orlistat and trastuzumab acted synergistically to induce apoptosis and impede the survival of drug-resistant ovarian cancer cells. This evidence concerns the gene ERBB2 and ovarian carcinoma.